EAGAN, MN, United States
EAGAN, MN, United States

Time filter

Source Type

News Article | April 20, 2017
Site: marketersmedia.com

— US & Canada Beta Glucan market will register the CAGR of more than 6.1% during the forecast period. Developing interest for nutraceutical and functional product is found in the most recent decade. This happened because of quick way of life and idea of curing illness through food. Individuals everywhere throughout the world have a mission for new choices and idea of functional ingredients fulfill their dietary needs as these positively affect metabolic parameters and eventually supportive in diseases, for example, cancer, diabetes and cardiovascular disease. Beta Glucan is a significant functional ingredient that has various medical advantages. Its part in controlling hyperlipedemia and hyperglycemia is unprecedented. The general purpose of beta glucan is to enhance and improve the human immune system. Currently, people are getting more aware and conscious about health food intake and boost their immune system, while performing these activities the demand of Beta-Glucan has increased globally. The prominent players present in the US & Canada Beta Glucan Market includes • Lesaffre USA • DSM USA • Bio Springer • Lallemand • Associated British Foods • Biothera Inc, Tate & Lyle • Garuda International Inc, Alltech • Ceapro Inc • Super Beta glucan • ConAgra Foods, Inc • Cargill The strategy adopted by DSM is that working with its own clients and customers to create awareness and mindfulness amongst customers of the advantages of oat beta-glucan and the Friend OatWell brand has been created to convey the advantages on buyer product bundling. OatWell is accessible in flour or powder design, reasonable for use in applications running from breads, biscuits and oats to pasta, refreshments, instant powder drinks and dietary supplements. The other players’ strategies are also discussed in the report. To calculate US & Canada beta glucan market size, MRFR has considered prominent players in the in the US & Canada market and to offer accuracy, our research is supported by industry experts who offer insight on industry structure and technology assessment, competitive landscape, penetration, emerging products and trends. MRFR analysis is based (80 to 85%) on primary & (15 to 20%) on secondary research as well as years of professional expertise in their respective industries. In addition to analyze current and historical trends, our analysts predict where the market is headed over the next forecasted years. It varies by segment for these categories geographically presented in the list of market tables. Top-down and bottom-up are important strategies of processing the information and knowledge ordering, used in a variety of fields including humanistic, software and scientific theories and management and organization. In practice, they can be seen as a style of thinking, teaching, or leadership. Speaking about this particular report we have conducted primary surveys(interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market. 1. INTRODUCTION 1.1 DEFINITION 2. RESEARCH METHODOLOGY 3. THE US & CANADA BETA GLUCAN MARKET: OVERVIEW 4. MARKET DYNAMICS 4.1 DRIVERS 4.1.1 INCREASING AWARENESS AND HEALTH CONSCIOUSNESS 4.2 RESTRAINTS 5. THE US & CANADA BETA GLUCAN MARKET: VALUE/SUPPLY CHAIN ANALYSIS 6. THE US & CANADA BETA GLUCAN MARKET: PORTER'S 5 FORCES ANALYSIS 7. THE US & CANADA BETA GLUCAN MARKET: MARKET VALUE & VOLUME FORECAST (2016-2027) (US $ MILLION) 7.1 Y-O-Y GROWTH PROJECTIONS 7.2 OPPORTUNITY ANALYSIS 7.3 MARKET SHARE ANALYSIS 8. THE US & CANADA BETA GLUCAN MARKET: BY PRODUCT TYPES 8.1 INTRODUCTION 8.2 Y-O-Y GROWTH PROJECTIONS BY PODUCT TYPES 9. THE US & CANADA BETA GLUCAN MARKET: BY APPLICATIONS 9.1 INTRODUCTION 10. THE US & CANADA BETA GLUCAN MARKET: BY FUNCTIONALITY TYPE 10.1 INTRODUCTION 11. THE US & CANADA BETA GLUCAN MARKET: BY COUNTRY 11.1 INTRODUCTION 11.2 Y-O-Y GROWTH PROJECTIONS BY COUNTRY 11.3 MARKET SIZE BY REGION 12. COMPANY LANDSCAPE 13. COMPANY PROFILE 13.1 LESAFFRE USA 13.2 DSM USA 13.3 BIO SPRINGER 13.4 LALLEMAND 13.5 ASSOCIATED BRITISH FOODS 13.6 BIOTHERA INC 13.7 TATE & LYLE 13.8 GARUDA INTERNATIONAL INC 13.9 ALLTECH 13.10 CEAPRO INC 13.11 SUPER BETA GLUCAN 13.12 CONAGRA FOODS 13.13 CARGILL For more information, please visit https://www.marketresearchfuture.com/reports/beta-glucan-market


Patent
Biothera | Date: 2014-11-04

The present invention relates to a process for decreasing off-flavors of dried beta glucan. The pH of the beta glucan is lowered prior to drying the beta glucan in order to reduce Maillard reactions which produce the off-flavors.


Patent
Biothera | Date: 2013-03-14

This disclosure describes, in one aspect, a composition that includes a -glucan component and an antibody component that specifically binds to the -glucan. In another aspect, this disclosure describes a method of increasing a subjects response to -glucan immunotherapy. Generally, the method includes identifying the subject as a low binder of -glucan and administering to the subject a composition that comprises a -glucan moiety conjugated to the therapeutic antibody. In some cases, the therapeutic antibody can be an anti-tumor antibody.


Patent
Biothera | Date: 2013-03-14

This disclosure describes, in one aspect, a method for identifying -glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble -glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble -glucan to bind to the immune cells, and detecting soluble -glucan bound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of -glucan, and co-administering to the subject a soluble -glucan and an antibody preparation capable of converting the subject from a low binder to a high binder.


Patent
Biothera | Date: 2012-05-09

Described herein are beta-glucan compounds, compositions, and methods. Generally, the methods exploit the observation that beta-glucan compounds can bind to B cells. Thus, the methods generally include administering a beta-glucan compound to a subject in an amount effective for the beta-glucan compound to bind to a B cell and modulate at least one biological function of the B cell.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 149.45K | Year: 2014

DESCRIPTION (provided by applicant): Fungal infections, particularly in immunocompromised patients, are a serious and growing problem. Although antifungal therapeutics have improved greatly, failures and relapse are common. Aspergillus fumigatus is a primary cause of these infections in several patient populations: transplants, leukemics, genetic deficiencies such as chronic granulomatous disease and others, with mortality remaining high. Preventative antifungal vaccines are an attractive, but as yet unrealized, option. The goal of this proposal is to develop a prototype glucan-protein vaccine by conjugating a protein to a particulate -glucan immunomodulator (i.e., WGP), a cell wall component of many pathogenic fungi. Preliminary work using WGP alone or conjugated to a non-specific protein, bovine serum albumin (BSA), indicated that a glucan-protein vaccine was active against Aspergillus and Coccidioides. The work described in this proposal will examine the potential of conjugating a specific, immunodom


Patent
Biothera | Date: 2014-12-01

This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subjects immune response to -glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti--glucan antibody compared to a reference standard, computing a Relative Antibody Unit (RAU) value for anti--glucan antibody in the sample, and identifying the subject as biomarker positive if the RAU value is greater than a predetermined RAU value for the biomarker anti--glucan antibody.


Studies involving placebo-controlled, double-blinded designs to evaluate the effect of beta-glucan compositions on upper-respiratory tract infections and psychological wellness were carried out. During the course of the reporting periods of these studies, subjects in the treatment groups reported fewer URTI symptoms, better overall health and a more positive psychological assessment based on a POMS survey.


Modified and/or derivativized -glucans with an enhanced capacity to modulate human immune response as compared to the parent, unmodified and/or underivatized -glucans are demonstrated.


Patent
Biothera | Date: 2013-04-24

Particulate -glucan is solubilized at elevated pressure and temperature to form particulate-soluble -glucan. The particulate-soluble -glucan is capable of being dried to a powder form and subsequently re-solubilized.

Loading Biothera collaborators
Loading Biothera collaborators